Log in

NYSEAMERICAN:XTNT - Xtant Medical Stock Price, Forecast & News

$1.68
+0.02 (+1.21 %)
(As of 12/6/2019 04:00 PM ET)
Add
Today's Range
$1.66
Now: $1.68
$1.70
50-Day Range N/A
52-Week Range
$1.61
Now: $1.68
$4.75
Volume1,023 shs
Average Volume6,570 shs
Market Capitalization$22.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNYSEAMERICAN:XTNT
CUSIPN/A
Phone+1-406-3880480

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$22.10 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive XTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for XTNT and its competitors with MarketBeat's FREE daily newsletter.


Xtant Medical (NYSEAMERICAN:XTNT) Frequently Asked Questions

What is Xtant Medical's stock symbol?

Xtant Medical trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XTNT."

When did Xtant Medical's stock split? How did Xtant Medical's stock split work?

Xtant Medical shares reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Xtant Medical stock prior to the reverse split would have 8 shares after the split.

How were Xtant Medical's earnings last quarter?

Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) posted its quarterly earnings data on Thursday, November, 7th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.14. The medical device company had revenue of $15.72 million for the quarter. View Xtant Medical's Earnings History.

When is Xtant Medical's next earnings date?

Xtant Medical is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Xtant Medical.

What is the consensus analysts' recommendation for Xtant Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Xtant Medical.

Has Xtant Medical been receiving favorable news coverage?

Press coverage about XTNT stock has been trending negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Xtant Medical earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Xtant Medical.

What other stocks do shareholders of Xtant Medical own?

Who are Xtant Medical's key executives?

Xtant Medical's management team includes the folowing people:
  • Carl D. O'Connell, President, Chief Executive Officer (Age 53)
  • Darrel Lee Holmes, Chief Operating Officer (Age 62)
  • Gregory Juda Ph.D., Chief Scientific Officer (Age 39)
  • John K. Bakewell, Director (Age 55)
  • Michael Eggenberg, Director
  • Michael R. Mainelli Jr., Director (Age 55)
  • Robert E. McNamara, Director (Age 61)
  • Jeffrey J. Peters, Director

How do I buy shares of Xtant Medical?

Shares of XTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xtant Medical's stock price today?

One share of XTNT stock can currently be purchased for approximately $1.68.

How big of a company is Xtant Medical?

Xtant Medical has a market capitalization of $22.10 million. View Additional Information About Xtant Medical.

What is Xtant Medical's official website?

The official website for Xtant Medical is http://xtantmedical.com/.

How can I contact Xtant Medical?

Xtant Medical's mailing address is 664 Cruiser Ln, BELGRADE, MT 59714-9719, United States. The medical device company can be reached via phone at +1-406-3880480.


MarketBeat Community Rating for Xtant Medical (NYSEAMERICAN XTNT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about Xtant Medical and other stocks. Vote "Outperform" if you believe XTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel